

(19)



(11)

EP 2 508 512 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

10.10.2012 Bulletin 2012/41

(51) Int Cl.:

C07D 209/40^(2006.01)

A61K 31/404^(2006.01)

A61P 35/00^(2006.01)

(21) Application number: **11160557.2**

(22) Date of filing: **31.03.2011**

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

Designated Extension States:

BA ME

(72) Inventors:


- **Kadi, Adnan Ahmed
11333, Riyadh (SA)**
- **Abdel-Aziz, Hatem Abdel-Khader
11421, Riyadh (SA)**

(71) Applicant: **King Saud University
11421 Riyadh (SA)**

(74) Representative: **Goddard, Heinz J.
Boehmert & Boehmert
Pettenkoferstrasse 20-22
80336 München (DE)**

(54) **Novel N,N'-hydrazino-bis-isatin derivatives with selective activity against multidrug-resistant cancer cells**

(57) The invention, is directed to a compound of Formula (I),



wherein R is selected from the group consisting of hydrogen atom and unsubstituted or substituted phenyl group; R₁ is selected from the group consisting of hydrogen atom and unsubstituted or substituted phenyl group; X is selected from the group consisting of hydrogen atom or halogen atom; and Y is selected from the group consisting of hydrogen atom, halogen atom, C₁-C₄ alkyl group, nitro group, and -OCF₃ group, as well as for its use in therapy, preferably for the treatment of cancer, and to a related pharmaceutical composition, the use of the compound for the manufacture of a medicament for the respective medical indication, and a method of synthesis of the compounds of the invention.

EP 2 508 512 A1

Description

Background

5 **[0001]** Cancer is one of the most dreaded diseases of mankind, it is a leading cause of death throughout the world, currently, one in 4 deaths in the United States is due to cancer [1]. More than ten million new cancer cases occur annually, roughly half of which is in the developed countries, and the disease causes over six million deaths a year [2,3]. Recent studies revealed that cancer has become an ever-increasing problem in Saudi Arabia [4-6]. In 2005, cancer killed approximately 12,000 of Saudi people, 8000 of those people were under age of 70 [7]. Furthermore, cancer is growing in Saudi Arabia with 7,000 new cases being reported each year and the figure will reach 30,000 in 15 years, according to one expert [8]. The treatment of disseminated cancer has become increasingly aimed at molecular targets derived from studies of the oncogenes and tumor suppressors known to be involved in the development of human cancers [9]. This increase in specificity of cancer treatment, from the use of general cytotoxic agents such as nitrogen mustard in the 1940s, to the development of natural-product anticancer drugs in the 1960s such as *Vinca* alkaloids and anthracyclines, which are more cytotoxic to cancer cells than normal cells, to the use of specific monoclonal antibodies [10] and immunotoxins [11] targeted to cell surface receptors and specific agents that inactivate kinases in growth-promoting pathways [12], has improved the response rate in cancer and reduced side effects of anticancer treatment but has not yet resulted in cure of the majority of patients with metastatic disease. A study of the mechanisms by which cancers elude treatment has yielded a wealth of information about why these therapies fail and is beginning to yield valuable information about how to circumvent drug resistance in cancer cells and/or design agents that are not subject to the usual means of resistance.


20 **[0002]** The failure of the curative treatment of cancer patients often occurs as a result of intrinsic or acquired drug resistance of the tumor to chemotherapeutic agents. The resistance of tumors occurs not only to a single cytotoxic drug used, but also occurs as a cross-resistance to a whole range of drugs with different structures and cellular targets. This phenomenon is called multiple drug resistance (MDR). Once MDR appears, using high doses of drugs to overcome resistance is ineffective, toxic effects appear and resistance are further stimulated. Multidrug resistance (MDR) severely limits the effectiveness of chemotherapy in a variety of common malignancies and is responsible for the overall poor efficacy of cancer chemotherapy [13-17].

25 **[0003]** The cytotoxic drugs that are most frequently associated with MDR are hydrophobic, amphipathic natural products, such as the taxanes (paclitaxel and docetaxel), vinca alkaloids (vinorelbine, vincristine, and vinblastine), anthracyclines (doxorubicin, daunorubicin, and epirubicin), epipodophyllotoxins (etoposide and teniposide), antimetabolites (methotrexate, fluorouracil, cytosar, 5-azacytosine, 6-mercaptopurine, and gemcitabine), topotecan, dactinomycin, and mitomycin C [16,18-20].

30 **[0004]** In spite of the large number of available chemotherapeutic agents the medical need is still largely unmet. The main reasons are: the lack of selectivity of conventional drugs, leading to toxicity; the metastatic spreading, implying early tumor implantation in organs other than primary site; the heterogeneity of the disease, comprising about 100 types of cancer; the intrinsic or acquired resistance to chemotherapy developed after few therapeutic cycles, i.e. multi-drug resistance (MDR) [21]. Therefore, new drugs that offer improvements over current therapies are desperately needed. New chemical entities with novel mechanisms of action will most likely possess activity against MDR cancer. [MDR severely limits the effectiveness of chemotherapy in a variety of common malignancies and is responsible for the overall poor efficacy of cancer chemotherapy [19-23].]

Summary of the Invention

35 **[0005]** Accordingly, the present invention describes design, synthesis and antiproliferative activity of novel *N,N'*-hydrazino-bis(isatin) derivatives with the following general structure (I)



wherein

R is selected from the group consisting of hydrogen atom and unsubstituted or substituted phenyl group;

R₁ is selected from the group consisting of hydrogen atom and unsubstituted or substituted phenyl group;

X is selected from the group consisting of hydrogen atom or halogen atom; and

5 Y is selected from the group consisting of hydrogen atom, halogen atom, C₁-C₄ alkyl group, nitro group, and -OCF₃ group.

[0006] In one embodiment of the present invention, R is selected from the group consisting of hydrogen atom and unsubstituted phenyl group.

[0007] In another embodiment of the invention, R₁ is selected from the group consisting of hydrogen atom and unsubstituted phenyl group.

10 **[0008]** In a further embodiment of the invention, X is selected from the group consisting of hydrogen atom and fluorine atom.

[0009] In still further embodiment of the invention, Y is selected from the group consisting of hydrogen atom, fluorine atom, chlorine atom, bromine atom, methyl group, nitro group and -OCF₃ group.

15 **[0010]** Moreover, the present invention is also related to a compound according to the present invention for use in therapy, preferably for the treatment of cancer and most preferably for the treatment of multidrug resistant cancer.


[0011] Further, the present invention is directed to a pharmaceutical composition comprising a compound according to the present invention together with at least one pharmaceutically acceptable excipient.

20 **[0012]** In a further embodiment, the present invention is directed to the use of a compound according to the present invention for the manufacture of a medicament for the treatment of cancer, most preferably for the treatment of multidrug resistant cancer.


[0013] The present invention is also related to a method of synthesis of a compound according to claim 1, wherein

(i) an isatin of Formula (1) is reacted with hydrazine or a hydrazine hydrate to obtain a hydrazone of Formula (2),

25



(1)




(2)

30

35 wherein R and X are as defined in claim 1; and

(ii) reacting the hydrazone obtained in step (i) with an isatin of formula (1')

40



(1')

45

to obtain a compound of formula (I), wherein R₁ and Y are as defined hereinabove.

50 **[0014]** Preferably, step (i) and (ii) are conducted in a polar organic solvent, preferably methanol in step (i) and ethanol/acid in step (ii).


[0015] In a preferred embodiment, step (i) and (ii) are independently conducted either under reflux conditions or with a microwave assisted method.

55


Detailed Description of the Invention

1. General Synthesis of the Target Compounds

5 [0016] The general procedures for the preparation of the target derivatives of isatin is described in Schemes 1 and 2.



20 **Scheme 1.** Reagents and conditions: (a) $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$, MeOH, MWI, 50W (90°C), 1 min, 85-90%; (b) $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$, MeOH, reflux 1 h, 69-77%.



35

40 **Scheme 2.** (a) EtOH/AcOH, MWI, 50W (90°C), 7 min, 72-95%; (b) EtOH/AcOH, reflux 4-6 h, 66-89%.

45 [0017] The target compounds can be synthesized *via* the reaction of the appropriate isatin with hydrazine hydrate to get the corresponding (Z)-3-hydrazinyl-indene-1-H- or 1-phenyl-indolin-2-one (**2a-c**) [24], Scheme 1. **2a-c** can be achieved by conventional method or microwave, assisted method (MWI). Target compounds can also be obtained by conventional method or MWI through coupling the appropriate isatin derivatives with **2a-c** as illustrated by scheme 2.

50 [0018] The synthesized compounds were purified by flash chromatography and crystallized from ethanol. The structures were confirmed by spectroscopic methods of analyses. Structures of these targets are given in Table 1.

55

Table 1. Structure of reactants isatins **1a-h**, hydrazones **2a-c** and products **3-23**

5

10

15

20

25

30













35

40

45

50

55




Isatin 1a-h	Hydrazone 2a-c	Products 3-23
 1a	 2a	 3
 1b	 2a	 4
 1c	 2a	 5
 1d	 2a	 6

(continued)

5




Isatin **1a-h**Hydrazone **2a-c**Products **3-23**

10

**1e****2a****7**




15

20

**1f****2a****8**




25

30

**1g****2a****9**

35

40

**1h****2a****10**

45

50

55

(continued)




5

Isatin 1a-h




Hydrazone 2a-c

Products 3-23




10

**1b****2b****11**

15

**1c****2b****12**




25

**1d****2b****13**

30

35

40

**1e****2b****14**

45

50

55

(continued)

5

10

15

20

25













30

35

40

45

50

Isatin **1a-h**Hydrazone **2a-c**Products **3-23****1f****2b****15****1g****2b****16****1h****2b****17****1c****2c****18**

55

(continued)


5

Isatin 1a-h


Hydrazone 2a-c

Products 3-23


10



1d




2c




19

15


20



1e




2c




20

25


30



1f




2c




21

35


40



1g



2c




22

45

50

55

(continued)



[0019] The precipitate was filtered and dried. The crude product was recrystallized from EtOH/DMF to obtain compounds **3-23** in 66-89% yield.

[0020] **3.2. Microwave method:** A solution of hydrazones **2a-c** (1 mmole) and isatins **1a-h** (1 mmole) in ethanol (15 ml) were prepared. Few drops of glacial acetic acid were added and whole reaction mixture was irradiated under microwave irradiation at 90°C for 7 minutes. The reaction mixture was cooled. The solid that separated on cooling was filtered, washed with cold ethanol, dried and recrystallised from EtOH/DMF.

4. Spectroscopical Data of the Synthesized Compounds

(Z)-3-Hydrazoneindolin-2-one (**2a**)

[0021] IR (KBr) ν 3361-3199 (NH, NH₂), 1687 (C=O), 1609 (C=N) cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 6.87 (d, 1H, *J* = 7.0 Hz, ArH), 6.97 (t, 1H, *J* = 6.5 Hz, ArH), 7.16 (t, 1H, *J* = 6.5 Hz, ArH), 7.37 (d, 1H, *J* = 7.0 Hz, ArH), 9.57 (d, 1H, *J* = 14.0 Hz, D₂O exch., amino H), 10.56 (d, 1H, *J* = 14.0 Hz, D₂O exch., -amino H), 1.0.71 (s, D₂O exch., 1H, NH); ¹³C NMR δ 109.93, 117.43, 121.32, 126.17, 127.0, 162.75; MS *m/z* (%) 161 (M⁺, 39.7), 103.7 (64.3), 46.8 (100).

(Z)-5-Fluoro-3-hydrazoneindolin-2-one (**2b**)

[0022] IR (KBr) ν 3365-3153 (NH, NH₂), 1682 (C=O), 1585 (C=N) cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 6.85 (m, 1H, ArH), 6.97 (m, 1H, ArH), 7.15 (d, 1H, *J* = 7.5 Hz, ArH), 9.81 (d, 1H, *J* = 15.0 Hz, D₂O exch., amino H), 10.65 (d, 1H, *J* = 15.0 Hz, D₂O exch., amino H), 10.72 (s, D₂O exch., 1H, NH); ¹³C NMR δ 104.30 (²*J*_{F-C} = 25.3 Hz), 110.74 (³*J*_{F-C} = 8.3 Hz), 113.10 (²*J*_{F-C} = 24.2 Hz), 123.59 (³*J*_{F-C} = 9.2 Hz), 125.65, 134.69, 158.10 (¹*J*_{F-C} = 235.3 Hz), 162.95; MS *m/z* (%) 179 (M⁺, 11.8), 61.9 (55.7), 40.1 (100).

(Z)-3-Hydrazone-1-phenylindolin-2-one (**2c**)

[0023] IR (KBr) ν 3375-3208 (NH₂), 1674 (C=O), 1592 (C=N) cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 6.82 (m, 1H, ArH), 7.11 (m, 1H, ArH), 7.20 (m, 1H, ArH), 7.43-7.53 (m, 4H, ArH), 7.59 (m, 2H, ArH), 9.90 (d, 1H, *J* = 15.0 Hz, D₂O exch., amino H), 10.61 (d, 1H, *J* = 14.5 Hz, D₂O exch., amino H); ¹³C NMR δ 109.06, 117.51, 122.52, 124.63, 126.63, 126.98, 127.86, 129.44, 129.51, 133.79, 139.44, 159.98; MS *m/z* (%) 237.1 (M⁺, 100), 192 (60.1), 51 (93.6).

(3Z,3Z)-3,3'-(Hydrazine-1,2-diylidene)diindolin-2-one (**3**)

[0024] IR (KBr) ν 3276 (2NH), 1722 (2C=O), 1615 (2C=N) cm⁻¹; ¹H NMR (DMSO-*d*₆) δ 6.92 (d, 2H, *J* = 7.5 Hz, ArH), 7.02 (t, 1H, *J* = 7.5 Hz, ArH), 7.43 (t, 1H, *J* = 7.5 Hz, ArH), 7.51 (d, 1H, *J* = 7.5 Hz, ArH), 11.02 (s, 2H, 2NH); ¹³C NMR δ 111.09, 115.75, 122.53, 128.17, 134.39, 144.70, 145.16, 163.39; MS *m/z* (%) 290.5 (M⁺, 6.6), 46 (74.9), 40.1 (100).

(Z)-3-((Z)-(2-Oxoindolin-3-ylidene)hydrazone)-1-phenylindolin-2-one (**4**)

[0025] IR (KBr) ν 3448 (NH), 1734 (2C=O), 1606 (2C=N) cm⁻¹; MS *m/z* (%) 266.1 (M⁺, 3.5), 40.1 (100).

EP 2 508 512 A1

(Z)-5-Fluoro-3-((Z)-(2-oxoindolin-3-ylidene)hydrazono)indolin-2-one (5)

5 [0026] IR (KBr) ν 3420-3284 (2NH), 1722 (2C=O), 1616 (2C=N) cm^{-1} ; ^1H NMR (DMSO- d_6) δ 6.92-7.53 (m, 7H, ArH), 11.02 (s, D₂O exch., 2H, 2NH); ^{13}C NMR δ 111.09, 112.12 ($^3J_{\text{F-C}} = 7.4$ Hz), 115.0 ($^2J_{\text{F-C}} = 25.7$ Hz), 115.77, 116.20 ($^3J_{\text{F-C}} = 8.6$ Hz), 120.77 ($^2J_{\text{F-C}} = 23.7$ Hz), 122.52, 128.48, 1.34.59, 141.56, 144.70, 145.16, 145.44, 145.64, 157.50 ($^1J_{\text{F-C}} = 263.0$ Hz), 163.39, 163.44; MS m/z (%) 308.2 (M⁺, 5.0), 46 (100).

(Z)-5-Chloro-3-((Z)-(2-oxoindolin-3-ylidene)hydrazono)indolin-2-one (6)

10 [0027] IR (KBr) ν 3420-3244 (2NH), 1736 (2C=O), 1617 (2C=N) cm^{-1} ; ^1H NMR (DMSO- d_6) δ 6.86-7.58 (m, 7H, ArH), 11.03 (s, D₂O exch., 2H, 2NH); MS m/z (%) 325.2 (M⁺ +1, 6.8), 324.4 (M⁺, 15), 78 (100).

(Z)-5-Bromo-3-((Z)-(2-oxoindolin-3-ylidene)hydrazono) indolin-2-one (7)

15 [0028] IR (KBr) ν 3239 (2NH), 1735 (2C=O), 1612 (2C=N) cm^{-1} ; ^1H NMR (DMSO- d_6) δ 6.88-7.66 (m, 7H, ArH), 11.02 (s, D₂O exch., 1H, NH), 11.15 (s, D₂O exch., 1H, NH); ^{13}C NMR δ 111.11, 113.05, 113.64, 115.79, 117.48, 122.52, 125.05, 128.62, 130.34, 134.62, 136.52, 144.35, 144.76, 145.43, 145.91, 163.06, 163.43; MS m/z (%) 369 (M⁺, 19.0), 40.1 (100).

(Z)-5-Methyl-3-((Z)-(2-oxoindolin-3-ylidene)hydrazono)indolin-2-one (8)

20 [0029] IR (KBr) ν 3286 (2NH), 1723 (2C=O), 1615 (2C=N) cm^{-1} ; ^1H NMR (DMSO- d_6) δ 2.21 (s, 3H, CH₃), 6.82-7.53 (m, 7H, ArH), 11.01 (s, D₂O each., 2H, 2NH); ^{13}C NMR δ 20.53, 110.87, 111.08, 115.75, 122.53, 128.17, 128.48, 131.42, 134.39, 134.74, 142.94, 144.70, 144.81, 145.16; MS m/z (%) 303.9 (M⁺, 4.0), 40.1 (100).

(Z)-5-Nitro-3-((Z)-(2-oxoindolin-3-ylidene)hydrazono)indolin-2-one (9)

25 [0030] IR (KBr) ν 3447 (2NH), 1731 (2C=O), 1617 (2C=N) cm^{-1} ; ^1H NMR (DMSO- d_6) δ 6.93-8.36 (m, 7H, ArH), 11.06 (s, D₂O exch., 1H, NH), 11.69 (s, D₂O exch., 1H, NH); MS m/z (%) 335 (M⁺ 9.7), 47.8 (100).

(Z)-3-((Z)-(2-Oxoindolin-3-ylidene)hydrazono)-5-(trifluoromethoxy) indolin- 2-one (10)

30 [0031] IR (KBr) ν 3446-3245 (2NH), 1740 (2C=O), 1617 (2C=N) cm^{-1} ; ^1H NMR (DMSO- d_6) δ 6.92-7.56 (m, 7H, ArH), 11.02 (s, D₂O exch., 1H, NH), 11.20 (s, D₂O exch., 1H, NH); ^{13}C NMR δ 111.11, 112.18, 115.72, 116.42, 121.12, 122.54, 127.20, 128.67, 134.69, 142.95, 144.26, 145.15, 145.49, 146.00, 159.38, 163.36, 163.43; MS m/z (%) 374 (M⁺, 7.9), 44.9 (100).

(3Z,3'Z)-3,3'-(Hydrazine-1,2-diylidene)bis(1-phenylindolin-2-one) (11)

35 [0032] IR (KBr) ν 1731 (2C=O), 1605 (2C=N) cm^{-1} ; ^1H NMR (DMSO- d_6) δ 6.82-7.78 (m, 18H, ArH); ^{13}C NMR δ 110.03, 115.47, 123.53, 126.92, 128.48, 128.62, 129.67, 133.48, 134.38, 144.11, 146.18, 161.53; MS m/z (%) 442.2 (M⁺, 3.3), 64 (100).

(Z)-5-Fluoro-3-((Z)-(2-oxo-1-phenylindolin-3-ylidene)hydrazono)indolin-2-one (12)

40 [0033] IR (KBr) ν 3282 (NH), 1735 (2C=O), 1608 (2C=N) cm^{-1} ; ^1H NMR (DMSO- d_6) δ 6.82-7.67 (m, 12H, ArH), 11.07 (s, D₂O exch., 1H, NH); MS m/z (%) 384.2 (M⁺, 3.5), 48 (100).

(Z)-5-Chloro-3-((Z)-(2-oxo-1-phenylindolin-3-ylidene)hydrazono)indolin-2-one (13)

45 [0034] IR (KBr) ν 3448 (NH), 1736 (2C=O), 1609 (2C=N) cm^{-1} ; ^1H NMR (DMSO- d_6) δ 6.83-7.63 (m, 12H, ArH), 11.18 (s, D₂O exch., 1H, NH); MS m/z (%) 400.1 (M⁺, 5.1), 63 (100).

(Z)-5-Bromo-3-((Z)-(2-oxo-1-phenylindolin-3-ylidene)hydrazono)indolin-2-one (14)

50 [0035] IR (KBr) ν 3448 (NH), 1734 (2C=O), 1.608 (2C=N) cm^{-1} ; MS m/z (%) 444.7 (M⁺, 1.8), 43.8 (100).

EP 2 508 512 A1

(Z)-5-Methyl-3-((Z)-(2-oxo-1-phenylindolin-3-ylidene)hydrazono)indolin-2-one (15)

[0036] IR (KBr) ν 3447 (NH), 1736 (2C=O), 1609 (2C=N) cm^{-1} ; ^1H NMR (DMSO- d_6) δ 2.20 (s, 3H, CH_3), 6.83-7.63 (m, 12H, ArH), 11.18 (s, D_2O exch., 1H, NH); MS m/z (%) 379.9 (M^+ , 7.4), 62.9 (100).

(Z)-5-Nitro-3-((Z)-(2-oxo-1-phenylindolin-3-ylidene)hydrazono)indolin-2-one (16)

[0037] IR (KBr) ν 3447 (NH), 1740 (2C=O), 1609 (2C=N) cm^{-1} ; MS m/z (%) 411.1 (M^+ , 1.7), 45.8 (100).

((Z)-3-((Z)-(2-Oxo-1-phenylindolin-3-ylidene)hydrazono)-5-(trifluoromethoxy)indolin-2-one (17)

[0038] IR (KBr) ν 3236 (NH), 1747 (2C=O), 1608 (2C=N) cm^{-1} ; MS m/z (%) 449.6 (M^+ , 2.7), 49.9 (100).

(3Z,3'Z)-3,3'-(Hydoazine-1,2-diylidene)bis(5-fluoroindolin-2-one) (18)

[0039] IR (KBr) ν 3252 (2NH), 1739 (2C=O), 1625 (2C=N) cm^{-1} ; ^1H NMR (DMSO- d_6) δ 6.93-7.33 (m, 6H, ArH), 11.04 (s, D_2O exch., 2H, 2NH); ^{13}C NMR δ 112.12 ($^3J_{\text{F-C}} = 7.2$ Hz), 115.20 ($^2J_{\text{F-C}} = 25.5$ Hz), 116.24 ($^3J_{\text{F-C}} = 9.2$ Hz), 120.90 ($^2J_{\text{F-C}} = 23.8$ Hz), 141.82, 145.93, 157.50 ($^1J_{\text{F-C}} = 238.0$ Hz), 163.49; MS m/z (%) 326 (M^+ , 11), 44.9 (100).

(Z)-5-Chloro-3-((Z)-(5-fluoro-2-oxoindolin-3-ylidene)hydrozono)indolin-2-one (19)

[0040] IR (KBr) ν 3245 (2NH), 1736 (2C=O), 1618 (2C=N) cm^{-1} ; ^1H NMR (DMSO- d_6) δ 6.94-7.54 (m, 6H, ArH), 11.04 (s, D_2O exch., 1H, NH), 11.14 (s, D_2O exch., 1H, NH); ^{13}C NMR δ 112.08 ($^3J_{\text{F-C}} = 7.5$ Hz), 112.60, 115.35 ($^2J_{\text{F-C}} = 25.7$ Hz), 116.26 ($^3J_{\text{F-C}} = 8.9$ Hz), 117.05, 120.90 ($^2J_{\text{F-C}} = 23.9$ Hz), 126.03, 127.82, 133.89, 141.81, 144.24, 145.59, 146.13, 157.50 ($^1J_{\text{F-C}} = 237.9$ Hz), 163.24, 163.50; MS m/z (%) 342 (M^+ , 17.9), 63 (100).

(Z)-5-Bromo-3-((Z)-(5-fluoro-2-oxoindolin-3-ylidene)hydrazono)indolin-2-one (20)

[0041] IR (KBr) ν 3245 (2NH), 1735 (2C=O), 1616 (2C=N) cm^{-1} ; ^1H NMR (DMSO- d_6) δ 6.89-7.66 (m, 6H, ArH), 11.04 (s, D_2O exch., 1H, NH), 11.14 (s, D_2O exch., 1H, NH); ^{13}C NMR δ 112.14 ($^3J_{\text{F-C}} = 7.0$ Hz), 113.06, 113.61, 115.37 ($^2J_{\text{F-C}} = 25.3$ Hz), 116.24 ($^3J_{\text{F-C}} = 8.9$ Hz), 117.54, 120.90 ($^2J_{\text{F-C}} = 23.7$ Hz), 130.57, 136.69, 141.81, 144.61, 145.50, 146.18, 157.50 ($^1J_{\text{F-C}} = 238.0$ Hz), 163.11, 163.50; MS m/z (%) 387 (M^+ , 8.5), 46.9 (100).

(Z)-5-Fluoro-3-((Z)-(5-methyl-2-oxoindolin-3-ylidene)hydrazono)indolin-2-one (21)

[0042] IR (KBr) ν 3392-31186 (2NH), 1735 (2C=O), 1623 (2C=N) cm^{-1} ; ^1H NMR (DMSO- d_6) δ 2.22 (s, 3H, CH_3), 6.81-7.33 (m, 6H, ArH), 10.91 (s, D_2O exch., 1H, NH), 11.02 (s, D_2O exch., 1H, NH); MS m/z (%) 322.3 (M^+ , 6.9), 40.1 (100).

(Z)-5-Fluoro-3-((Z)-(5-nitro-2-oxoindolin-3-ylidene)hydrazono)indolin-2-one (22)

[0043] IR (KBr) ν 3248 (2NH), 1737 (2C=O), 1624 (2C=N) cm^{-1} ; ^1H NMR (DMSO- d_6) δ 6.93-8.35 (m, 6H, ArH), 11.08 (s, D_2O exch., 1H, NH), 11.71 (s, D_2O exch., 1H, NH); MS m/z (%) 353.5 (M^+ , 12.4), 63 (100).

(Z)-5-Fluoro-3-((Z)-(2-oxo-5-(trifluoromethoxy)indolin-3-ylidene)hydrazono)indolin-2-one (23)

[0044] IR (KBr) ν 3246 (2NH), 1735 (2C=O), 1624 (2C=N) cm^{-1} ; MS m/z (%) 392.4 (M^+ , 8.9), 62.9 (100).

5. *In vitro* Cell Lines and MTT Cytotoxicity Assay.

[0045] The cytotoxicity of the prepared compounds was evaluated at Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, Group in Biomolecular, USA, using the following protocol:

[0046] KB-3-1 cells (a HeLa derivative) and its MDR derivative (KB-V1) were grown as previously described [24]. Cell survival was measured by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay as previously described [24]. Briefly, cells were seeded in 100 μL of growth medium at a density of 5000 cells/well in 96-well plates and allowed to establish for 24 h, at which time serially diluted drugs were added in an additional 100 μL of growth medium. Cells were then incubated for 72 h at 37 $^\circ\text{C}$ in humidified 5% CO_2 , at which time the growth medium was drawn





EP 2 508 512 A1

and replaced with MTT in IMDM growth medium and incubated for 4 h. The MTT solution was then drawn from the wells, and 100 μ L of acidified ethanol solution was added to each well and after 15 min absorption at 560 nm was measured. IC₅₀ cytotoxicity values were determined as the drug concentration that reduced the absorbance to 50% of that in untreated control wells and derived from at least three separate experiments. hours, treated with the specified compound or vehicle (0.1% DMSO final) control, and incubated at 37°C an additional 72 hours. The effect of treatment on cell viability was determined using the luminescent Cell Titer Glo Assay (Promega). Results are given in Table 2.

Results







[0047] Variable and promising activity and selectivity revealed by the synthesized compounds against MDR cells, results are given in Table 2. Accordingly the synthesized bis-isatin derivatives are potential candidates for treatment MDR cancer.

Table 2: Structures of compounds considered in this study, along with IC₅₀ values determined against the parental KB-3-1 cell line, and the P-glycoprotein-expressing cell line KB-V1^a

Compound	Structure	IC ₅₀ KB3-1 (mM)	IC ₅₀ KBV1 (mM)	RR
2a		>500	125.18 \pm 39.39	N/A
2b		348.99 \pm 51.65	198.68 \pm 54.02	1.76
2c		150.42 \pm 67.67	31.35 \pm 13.38	4.80
3		17.12 \pm 0.83	17.26 \pm 1.59	0.99







EP 2 508 512 A1

(continued)

Compound	Structure	IC ₅₀ KB3-1 (mM)	IC ₅₀ KBV1 (mM)	RR
4		8.70 ± 2.21	10.80 ± 1.10	0.81
5		28.12 ± 2.48	25.29 ± 10.10	1.11
6		9.67 ± 1.74	7.72 ± 0.50	1.25
7		9.71 ± 0.31	7.58 ± 1.43	1.28
8		12.12 ± 3.14	14.93 ± 1.26	0.81
9		29.22 ± 2.81	30.39 ± 6.75	0.96






EP 2 508 512 A1

(continued)

Compound	Structure	IC ₅₀ KB3-1 (mM)	IC ₅₀ KBV1 (mM)	RR
10		9.75 ± 0.11	5.67 ± 1.18	1.72
11		25.56 ± 2.39	22.02 ± 2.37	1.16
12		10.20 ± 1.52	11.24 ± 0.61	0.91
13		6.79 ± 0.63	6.07 ± 1.19	1.12
14		7.93 ± 2.11	8.71 ± 0.27	0.91
15		8.37 ± 0.62	8.06 ± 1.68	1.04




EP 2 508 512 A1

(continued)

Compound	Structure	IC ₅₀ KB3-1 (mM)	IC ₅₀ KBV1 (mM)	RR
16		37.12 ± 4.05	48.61 ± 2.32	0.76
17		7.67 ± 0.88	4.80 ± 0.12	1.60
18		20.42 ± 4.62	16.54 ± 6.28	1.23
19		17.40 ± 4.41	11.28 ± 3.26	1.54
20		15.39 ± 3.97	18.64 ± 2.01	0.83

EP 2 508 512 A1

(continued)

Compound	Structure	IC ₅₀ KB3-1 (mM)	IC ₅₀ KBV1 (mM)	RR
21		18.92 ± 0.46	17.85 ± 0.82	1.06
22		56.00 ± 1.50	38.63 ± 13.54	1.45
23		15.23 ± 1.34	11.63 ± 2.55	1.31

[0048] ^a The MDR1 selectivity (RR) is calculated as the ratio of a compound's IC₅₀ against KB-3-1 cells divided by its IC₅₀ against KB-V1 cells. A value of >1 indicates that the compound kills P-gp-expressing cells more effectively than parental cells, so-called MDR1-selective activity. A value of <1 indicates that the P-gp-expressing cells are resistant to the compound, relative to parental cells, as is normally observed for P-gp substrates. "N/A" denotes not tested for selectivity.

References;

[0049]

J. Ahmedin, R. Siegel, E. Ward, Y. Hao, J. Xu, T. Murray, M. J. Thun, CA Cancer J Clin, 58,71(2008).

R. Sinha, K. El-Bayoumy, Current Cancer Drug Targets, 4, 13(2004).

P. Cozzi, N. Mongelli, A. Suarato, Curr. Med. Chem. - Anti-Cancer Agents, 4,93(2004).

W. A. Milaat, Knowledge of secondary-school female students on breast cancer and breast self-examination in Jeddah, Saudi Arabia. East. Mediterr. Health J., 6, 338-343(2000).

A. A. Ezzat, E. M. Ibrahim, M. A. Raja, S. Al-Sobhi, A. Rostom, R. K. Stuart. Locally advanced breast cancer in Saudi Arabia: high frequency of stage III in a young population. Med. Oncol., 16, 95-103(1999).

J. H. Talal. Adolescents and cancer: a survey of knowledge and attitudes about cancer in eastern province of Saudi Arabia. Saudi Soc. Family & Community Med., 7, 3 (2000).

http://www.who.int/ncd_surveillance/infobase/web/InfoBasePolicyMaker/reports/ReporterFullView.

<http://www.gulfoncology.org/blog/2007/06/cancer-incidence-on-rise-in-saudi.html>

M. Barinaga. From bench top to bedside. Science, 278,1036-39(1997)

J. M. Nabholz, D. Slamon. Neoadjuvant strategies for breast cancer: meeting the challenge of integrating chemo-

therapy and trastuzumab (Herceptin). *Semin. Oncol.* 28 (Suppl 3),1-12(2001)

1. Pastan, R. J. Kreitman. Immunotoxins for targeted cancer therapy. *Adv. Drug Deliv. Rev.*, 31,53-88(1998).

5 Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. *N. Engl. J. Med.* 344,1038-42(2001).

10 1. Akan, S. Akan, H. Akca, B. Savas, T. Ozben, N-acetylcysteine enhances multidrug resistance-associated protein mediated doxorubicin resistance. *Eur. J. Clin. Invest.* 34, 683-689((2004).

1. Akan, S. Akan, H. Akca, B. Savas, T. Ozben, Multidrug resistance-associated protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and Buthionine sulfoximine. *Cancer Cell Int.* 5, 22(2005).

15 M. Liscovitch, Y. Lavie, Cancer multidrug resistance: a review of recent drug discovery research. *IDrugs.* 5, 349-355 (2002).

H. Thomas, H.M. Coley, Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. *Cancer Control* 10, 159-165(2003).

20 C. H. Choi, ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. *Cancer Cell Int.* 5, 30(2005).

25 S. V. Ambudkar, S. Dey, C. A. Hrycyna, M. Ramachandra, I. Pastan, M. M. Gottesman, Biochemical, cellular, and pharmacological aspects of the multidrug transporter. *Annu. Rev. Pharmacol. Toxicol.* 39, 361-398(1999).

R. Krishna, L.D. Mayer, Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. *Eur. J. Pharm. Sci.* 11, 265-283 (2000).

30 A. A. Stavrovskaya, Cellular mechanisms of multidrug resistance of tumor cells. *Biochemistry (Mosc).* 65, 95-106 (2000).

35 S. Grimaudo, M. Tolomeo, A. Chimirri, M. Zappala, R. A. Gancitano, N. D'Alessandro, *European Journal of Cancer*, 34, 1756(1998).

Z. H. Zhu, In *Dan Xi Xin Fa*; Y. Wang, J.P. Zhu, L.Z. Jiang, Eds.; People's medical publishing, 2005, ISBN 7-117-06711-X/R_6712.

40 W. Tang, G. Eisenbrand, *Chinese drugs of plant origin: Chemistry, Pharmacology, and Use in Traditional and Modern Medicine*; Springer: Berlin, Heidelberg, New York, 1990.


H. A. Abdel-Aziz, A. Bari, T. Aboul-Fadl and S. Weng Ng. *Acta Crystallographica Section E* (2010).

45 J. A. Ludwig, G. Szakacs, S.E. Martin, B.F. Chu, C. Cardarelli, Z.E. Sauna, N.J. Caplen, H.M. Fales, S.V. Ambudkar, J.N. Weinstein, J. N.; Gottesman. *Cancer Res.*, 66,4808(2006).

Claims

50 1. A compound of Formula (I)

55



wherein

R is selected from the group consisting of hydrogen atom and unsubstituted or substituted phenyl group;



R₁ is selected from the group consisting of hydrogen atom and unsubstituted or substituted phenyl group;

X is selected from the group consisting of hydrogen atom or halogen atom; and

Y is selected from the group consisting of hydrogen atom, halogen atom, C₁-C₄ alkyl group, nitro group, and -OCF₃ group.

- 20
2. The compound according to claim 1, wherein R is selected from the group consisting of hydrogen atom and unsubstituted phenyl group.
3. The compound according to claim 1 or 2, wherein R₁ is selected from the group consisting of hydrogen atom and unsubstituted phenyl group.
- 25
4. The compound according to any of claims 1 to 3, wherein X is selected from the group consisting of hydrogen atom and fluorine atom.
5. The compound according to any of the preceding claims, wherein Y is selected from the group consisting of hydrogen atom, fluorine atom, chlorine atom, bromine atom, methyl group, nitro group and -OCF₃ group.
- 30
6. The compound according to any of the preceding claims for use in therapy.
7. The compound according to any of claims 1 to 5 for the treatment of cancer.
- 35
8. The compound according to claim 7 for the treatment of multidrug resistant cancer.
9. A pharmaceutical composition comprising a compound according to any of claims 1 to 5 together with at least one pharmaceutically acceptable excipient.
- 40
10. A use of a compound according to any of claims 1 to 5 for the manufacture of a medicament for the treatment of cancer.
11. The use according to claim 10 for the manufacture of a medicament of multidrug resistant cancer.
- 45
12. A method of synthesis of a compound according to claim 1, wherein

(i) an isatin of Formula (1) is reacted with hydrazine or hydrazine hydrate to obtain a hydrazone of Formula (2),




55

EP 2 508 512 A1

wherein R and X are as defined in claim 1; and

(ii) reacting the hydrazone obtained in step (i) with an isatin of formula (1')

5



10

15

to obtain a compound of Formula (I), wherein R₁ and Y are as defined in claim 1.

13. The method according to claim 12, wherein steps (i) and (ii) are conducted in a polar organic solvent, preferably methanol in step (i) and ethanol/acetic acid in step (ii).

20

14. The method according to claim 11 or 12, wherein step (i) and (ii) are independently conducted either under reflux conditions or with a microwave assisted method.

25

30

35

40

45

50

55



Europäisches
Patentamt
European
Patent Office
Office européen
des brevets

EUROPEAN SEARCH REPORT

Application Number
EP 11 16 0557

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	BUU-HOI, N. P. ET AL: "Thermolysis of isatin azine with the formation of isoindigo", BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE, (12), 5035-6 CODEN: BSCFAS; ISSN: 0037-8968, 1968, XP9150075, * compounds 1,5 * * page 5036, left-hand column, line 3 - right-hand column, line 3 * -----	1-5, 12-14	INV. C07D209/40 A61K31/404 A61P35/00
X	HANNA, M. A. ET AL: "Simple approach to some new arylazo spiro indoline-based dyes as alternatives for benzidine-based dyestuffs", PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS, 182(10), 2371-2391 CODEN: PSSLEC; ISSN: 1042-6507, 2007, XP9150060, * page 2373; figure 1 * * page 2380; figure 3 * * page 2386; compounds IIa-e * * page 2388; compounds VIa,b * -----	1-5, 12-14	TECHNICAL FIELDS SEARCHED (IPC) C07D A61K A61P
A	WO 2009/102433 A2 (US GOV HEALTH & HUMAN SERV [US]; INST OF ENZYMOLOGY BIOLOG RES [HU]; H) 20 August 2009 (2009-08-20) * abstract * -----	1-14	
A	WO 2006/009765 A2 (US HEALTH [US]; SZAKACS GERGELY [US]; ANNEREAU JEAN-PHILLIPE [FR]; LAB) 26 January 2006 (2006-01-26) * page 11, line 30 - page 12, line 1; compound NSC 657456 * * page 15; compound NSC 657456 * * page 16 - page 17 * * page 24 - page 26 * ----- -/--	1-14	
The present search report has been drawn up for all claims			
Place of search Munich		Date of completion of the search 8 July 2011	Examiner Papathoma, Sofia
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document	

2
EPO FORM 1503_03_02 (P04C01)



EUROPEAN SEARCH REPORT

Application Number
EP 11 16 0557

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	RAMSHID, P. K. ET AL: "Synthesis and in vitro evaluation of some isatin-thiazolidinone hybrid analogues as anti-proliferative agents", MEDICINAL CHEMISTRY, 6(5), 306-312 CODEN: MCEHAJ; ISSN: 1573-4064, 2010, XP009150044, * abstract * * page 309; figure 1; tables 1-2 * * page 307 - page 308; compounds CI-CV * -----	1-14	
A	WO 2007/117699 A2 (UNIV SOUTH FLORIDA [US]; H LEE MOFFITT CANCER CT AND RE [US]; WU JIE []) 18 October 2007 (2007-10-18) * abstract * * second compound; page 94 * * page 26 - page 47 * -----	1-14	
A	MERRITT J E ET AL: "The bisindolylmaleimide protein kinase C inhibitor, Ro 32-2241, reverses multidrug resistance in KB tumour cells", CANCER CHEMOTHERAPY AND PHARMACOLOGY, SPRINGER VERLAG, BERLIN, vol. 43, no. 5, 1 January 1999 (1999-01-01), pages 371-378, XP002482189, ISSN: 0344-5704, DOI: DOI:10.1007/S002800050909 * abstract; figure 1 * -----	1-14	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (IPC)
Place of search		Date of completion of the search	Examiner
Munich		8 July 2011	Papathoma, Sofia
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

2
EPO FORM 1503_03_82 (P04001)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 11 16 0557

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

08-07-2011

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2009102433 A2	20-08-2009	AU 2009213153 A1	20-08-2009
		CA 2713288 A1	20-08-2009
		EP 2240175 A2	20-10-2010
		US 2010316655 A1	16-12-2010
WO 2006009765 A2	26-01-2006	AU 2005265027 A1	26-01-2006
		CA 2570501 A1	26-01-2006
		EP 1766407 A2	28-03-2007
		US 2008214606 A1	04-09-2008
WO 2007117699 A2	18-10-2007	US 2008176309 A1	24-07-2008

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Non-patent literature cited in the description

- **J. AHMEDIN ; R. SIEGEL ; E. WARD ; Y. HAO ; J. XU ; T. MURRAY ; M. J. THUN.** *CA Cancer J Clin*, 2008, vol. 58, 71 [0049]
- **R. SINHA ; K. EL-BAYOUMY.** *Current Cancer Drug Targets*, 2004, vol. 4, 13 [0049]
- **P. COZZI ; N. MONGELLI ; A. SUARATO.** *Curr. Med. Chem. - Anti-Cancer Agents*, 2004, vol. 4, 93 [0049]
- **W. A. MILAAT.** Knowledge of secondary-school female students on breast cancer and breast self-examination in Jeddah. *Saudi Arabia. East. Mediterr. Health J.*, 2000, vol. 6, 338-343 [0049]
- **A. A. EZZAT ; E. M. IBRAHIM ; M. A. RAJA ; S. AL-SOBHI ; A. ROSTOM ; R. K. STUART.** Locally advanced breast cancer in Saudi Arabia: high frequency of stage III in a young population. *Med. Oncol.*, 1999, vol. 16, 95-103 [0049]
- **J. H. TALAL.** Adolescents and cancer: a survey of knowledge and attitudes about cancer in eastern province of Saudi Arabia. *Saudi Soc. Family & Community Med.*, 2000, vol. 7, 3 [0049]
- **M. BARINAGA.** From bench top to bedside. *Science*, 1997, vol. 278, 1036-39 [0049]
- **J. M. NABHOLTZ ; D. SLAMON.** New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin). *Semin. Oncol.*, 2001, vol. 28 (3), 1-12 [0049]
- **I. PASTAN ; R. J. KREITMAN.** Immunotoxins for targeted cancer therapy. *Adv. Drug Deliv. Rev.*, 1998, vol. 31, 53-88 [0049]
- **DRUKER BJ ; SAWYERS CL ; KANTARJIAN H et al.** Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. *N. Engl. J. Med.*, 2001, vol. 344, 1038-42 [0049]
- **I. AKAN ; S. AKAN ; H. AKCA ; B. SAVAS ; T. OZ-BEN.** N-acetylcysteine enhances multidrug resistance-associated protein mediated doxorubicin resistance. *Eur. J. Clin. Invest.*, 2004, vol. 34, 683-689 [0049]
- **I. AKAN ; S. AKAN ; H. AKCA ; B. SAVAS ; T. OZ-BEN.** Multidrug resistance-associated protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and Buthionine sulfoximine. *Cancer Cell Int.*, 2005, vol. 5, 22 [0049]
- **M. LISCOVITCH ; Y. LAVIE.** Cancer multidrug resistance: a review of recent drug discovery research. *IDrugs.*, 2002, vol. 5, 349-355 [0049]
- **H. THOMAS ; H.M. COLEY.** Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. *Cancer Control*, 2003, vol. 10, 159-165 [0049]
- **C. H. CHOI.** ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. *Cancer Cell Int.*, 2005, vol. 5, 30 [0049]
- **S. V. AMBUDKAR ; S. DEY ; C. A. HRYCYNIA ; M. RAMACHANDRA ; I. PASTAN ; M. M. GOTTESMAN.** Biochemical, cellular, and pharmacological aspects of the multidrug transporter. *Annu. Rev. Pharmacol. Toxicol.*, 1999, vol. 39, 361-398 [0049]
- **R. KRISHNA ; L.D. MAYER.** Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. *Eur. J. Pharm. Sci.*, 2000, vol. 11, 265-283 [0049]
- **A. A. STAVROVSKAYA.** Cellular mechanisms of multidrug resistance of tumor cells. *Biochemistry (Mosc.)*, 2000, vol. 65, 95-106 [0049]
- **S. GRIMAUDDO ; M. TOLOMEO ; A. CHIMIRRI ; M. ZAPPALA ; R. A. GANCITANO ; N. D'ALESSANDRO.** *European Journal of Cancer*, 1998, vol. 34, 1756 [0049]
- **Z. H. ZHU.** Dan Xi Xin Fa. People's medical publishing, 2005 [0049]
- **W. TANG ; G. EISENBRAND.** Chinese drugs of plant origin: Chemistry, Pharmacology, and Use in Traditional and Modern Medicine. Springer, 1990 [0049]
- **H. A. ABDEL-AZIZ ; A. BARI ; T. ABOUL-FADL ; S. WENG NG.** *Acta Crystallographica Section E*, 2010 [0049]
- **J. A. LUDWIG ; G. SZAKACS ; S.E. MARTIN ; B.F. CHU ; C. CARDARELLI ; Z.E. SAUNA ; N.J. CAPLEN ; H.M. FALES ; S.V. AMBUDKAR ; J.N. WEINSTEIN.** *Cancer Res.*, 2006, vol. 66, 4808 [0049]